Nomlabofusp
CLIN-1601-103
Phase 1 small_molecule terminated
Quick answer
Nomlabofusp for Friedreich Ataxia is a Phase 1 program (small_molecule) at Larimar Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Larimar Therapeutics
- Indication
- Friedreich Ataxia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated